Corient Private Wealth LP Reduces Holdings in Charles River Laboratories International, Inc. $CRL

Key Points

• Corient Private Wealth LP cut its Charles River Laboratories stake by 23.6% in the second quarter, selling 4,183 shares and retaining 13,579 shares valued at approximately $3.08 million. Institutional investors and hedge funds collectively own 98.91% of the company.
• Company insiders sold 165,990 shares worth about $42.6 million over the past 90 days, including sizable sales by Director James Foster and EVP Victoria Creamer.
• Charles River reported quarterly EPS of $3.02, beating estimates of $2.77, while revenue of $1 billion declined 2.7% year over year. Analysts maintain a “Moderate Buy” consensus, with an average price target of $273.81.

Corient Private Wealth LP lessened its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 23.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,579 shares of the medical research company's stock after selling 4,183 shares during the period. Corient Private Wealth LP's holdings in Charles River Laboratories International were worth $3,080,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of CRL. HighTower Advisors LLC increased its stake in shares of Charles River Laboratories International by 5.7% during the 2nd quarter. HighTower Advisors LLC now owns 3,781 shares of the medical research company's stock worth $857,000 after purchasing an additional 203 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Charles River Laboratories International in the 2nd quarter valued at approximately $3,855,000. Raiffeisen Bank International AG grew its holdings in Charles River Laboratories International by 9.1% during the 2nd quarter. Raiffeisen Bank International AG now owns 6,000 shares of the medical research company's stock valued at $1,353,000 after buying an additional 500 shares during the last quarter. Knollwood Investment Advisory LLC acquired a new stake in Charles River Laboratories International during the 2nd quarter valued at $225,000. Finally, Syon Capital LLC increased its position in Charles River Laboratories International by 2.4% during the second quarter. Syon Capital LLC now owns 3,547 shares of the medical research company's stock worth $804,000 after buying an additional 83 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Charles River Laboratories International news, Director James Foster sold 75,000 shares of the business's stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the completion of the sale, the director directly owned 31,596 shares in the company, valued at $7,109,100. The trade was a 70.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Victoria Creamer sold 4,179 shares of the firm's stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the completion of the transaction, the executive vice president directly owned 30,051 shares in the company, valued at approximately $7,788,017.16. This represents a 12.21% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 165,990 shares of company stock worth $42,606,388. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $277.71 on Monday. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. The firm has a market capitalization of $13.26 billion, a price-to-earnings ratio of -57.26, a price-to-earnings-growth ratio of 2.73 and a beta of 1.40. Charles River Laboratories International, Inc. has a one year low of $144.26 and a one year high of $303.30. The company has a 50 day moving average price of $264.71 and a 200 day moving average price of $209.48.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating analysts' consensus estimates of $2.77 by $0.25. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. Charles River Laboratories International's revenue for the quarter was down 2.7% on a year-over-year basis. During the same quarter last year, the business earned $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.33 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on CRL. Piper Sandler set a $300.00 price target on Charles River Laboratories International in a report on Monday, August 10th. Sanford C. Bernstein set a $250.00 price objective on Charles River Laboratories International in a research report on Wednesday, July 1st. Evercore reissued an "outperform" rating and issued a $320.00 target price on shares of Charles River Laboratories International in a research note on Friday, September 11th. Morgan Stanley upped their target price on shares of Charles River Laboratories International from $260.00 to $300.00 and gave the company an "overweight" rating in a report on Friday, August 7th. Finally, Barclays reaffirmed an "overweight" rating and set a $300.00 price target on shares of Charles River Laboratories International in a research note on Wednesday, August 5th. Eleven equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $273.81.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a global provider of drug discovery, nonclinical development and laboratory services for pharmaceutical, biotechnology and medical device companies, as well as academic and government research institutions. The company supports customers throughout the development process, from early-stage research and target identification through preclinical testing and regulatory preparation.

Its offerings include research models and related products, discovery and development services, toxicology and safety assessment, efficacy testing, bioanalysis, and laboratory testing.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.